Altria supports lawsuit challenging FDA tobacco review delays
Helix Innovations and NJOY filed the complaint to enforce statutory 180-day review timelines and remove unlawful market competition from unregulated foreign manufacturers.
See the latest news and media coverage for Altria. We track all announcements, press releases, and industry mentions in real time, all in one place.
Tobacco and nicotine products company
altria.comLast updated
In short: Altria raised its dividend, reported mixed Q2 2026 results with narrowed guidance, and expanded its smoke-free nicotine pouch portfolio.
Helix Innovations and NJOY filed the complaint to enforce statutory 180-day review timelines and remove unlawful market competition from unregulated foreign manufacturers.
The new director brings extensive leadership experience from Nestlé and Refresco. He will join compensation, innovation, and finance committees.
The FDA found the products contain lower levels of most harmful constituents than other oral and smokeless tobacco products, many too low to quantify.
The company targets mid-single digit EPS growth, consistent dividend increases, and sustained tobacco market leadership despite e-vapor regulatory challenges.
Altria is downgraded to Hold after reporting mixed FQ2 results and oral tobacco weakness. Click to read this analysis on MO.
Investors examine second-quarter earnings to identify rising capital expenditure trends among major retail and food corporations heading into 2026.
Marlboro-maker Altria on Wednesday sued the U.S. Food and Drug Administration, seeking to force the agency to overhaul a product review process that tob...
The judge found that the Juul sublicense authorized Reynolds' continued use of the relevant patent rights, eliminating the basis for future infringement royalties.
Track Altria and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Altria and other trending companies.